期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 4, 期 6, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a015156
关键词
-
资金
- Dystrophic Epidermolysis Bullosa Research Association (DebRA, U.K. and Austria)
- Sohana Fund
- Goldman Sachs Gives
- United Kingdom (U.K.) Government Technology Strategy Board
- Rosetrees Trust
- U.K. National Institute for Health Research (NIHR) Biomedical Research Centre
- St. Thomas' National Health Service (NHS) Foundation Trust
- King's College London
Harnessing the regenerative capacity of keratinocytes and fibroblasts from human skin has created new opportunities to develop cell-based therapies for patients. Cultured cells and bioengineered skin products are being used to treat patients with inherited and acquired skin disorders associated with defective skin, and further clinical trials of new products are in progress. The capacity of extracutaneous sources of cells such as bone marrow is also being investigated for its plasticity in regenerating skin, and new strategies, such as the derivation of inducible pluripotent stem cells, also hold great promise for future cell therapies in dermatology. This article reviews some of the preclinical and clinical studies and future directions relating to cell therapy in dermatology, particularly for inherited skin diseases associated with fragile skin and poor wound healing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据